This page lists all known medications that could potentially lead to 'Posterior uveitis' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

Owing to the propensity for visual loss, immunosuppressive treatment in the form of systemic and/or local therapy is often required for the management of noninfective intermediate and posterior ...

September 28, 2010 — The US Food and Drug Administration (FDA) has approved a dexamethasone 0.7 mg intravitreal implant (Ozurdex; Allergan, Inc) for the treatment of noninfectious ocular inflammation ...

An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Treatment with a single intravitreal injection of Yutiq can significantly reduce recurrence rates of ...

Objectives There is evidence that pars plana vitrectomy (PPV) has a beneficial effect on the clinical course of chronic endogenous posterior uveitis (EPU) possibly by physically removing any resident ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Durasert, a 3-year treatment for ...

An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...

Twenty-one patients with syphilitic posterior uveitis were investigated retrospectively to study the disease spectrum, associations with neurosyphilis, and therapeutic implications. Ophthalmologic ...

Posterior segment non-infectious uveitis (NIPU) is a chronic, inflammatory disease affecting the posterior segment of the eye, often involving the retina, and is a leading cause of blindness in ...

WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, ...

It is rare for patients with chronic lymphocytic leukemia (CLL) to present with ocular involvement, but a mutational test could help clinicians identify patients more quickly. Testing for myeloid ...